JP2023511074A5 - - Google Patents
Info
- Publication number
- JP2023511074A5 JP2023511074A5 JP2022543432A JP2022543432A JP2023511074A5 JP 2023511074 A5 JP2023511074 A5 JP 2023511074A5 JP 2022543432 A JP2022543432 A JP 2022543432A JP 2022543432 A JP2022543432 A JP 2022543432A JP 2023511074 A5 JP2023511074 A5 JP 2023511074A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- protease
- polypeptide sequence
- integrin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062961537P | 2020-01-15 | 2020-01-15 | |
| US62/961,537 | 2020-01-15 | ||
| PCT/US2021/013478 WO2021146455A1 (en) | 2020-01-15 | 2021-01-14 | Cytokine il-2 prodrugs comprising a cleavable linker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511074A JP2023511074A (ja) | 2023-03-16 |
| JP2023511074A5 true JP2023511074A5 (https=) | 2024-01-22 |
Family
ID=74562082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543432A Pending JP2023511074A (ja) | 2020-01-15 | 2021-01-14 | 切断可能リンカーを含むサイトカインプロドラッグ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043489A1 (https=) |
| EP (1) | EP4090673A1 (https=) |
| JP (1) | JP2023511074A (https=) |
| KR (1) | KR20220128413A (https=) |
| CN (2) | CN116655799A (https=) |
| AU (1) | AU2021208553A1 (https=) |
| BR (1) | BR112022013993A2 (https=) |
| CA (1) | CA3164522A1 (https=) |
| IL (2) | IL294763A (https=) |
| MX (1) | MX2022008773A (https=) |
| WO (1) | WO2021146455A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021016599A1 (en) * | 2019-07-25 | 2021-01-28 | Trutino Biosciences Inc | Il-2 cytokine prodrugs comprising a cleavable linker |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| EP4704979A1 (en) * | 2023-01-20 | 2026-03-11 | Boehringer Ingelheim International GmbH | Il-12 fc fusion proteins |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| AU2019288484B2 (en) * | 2018-06-22 | 2024-06-20 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
-
2021
- 2021-01-14 BR BR112022013993A patent/BR112022013993A2/pt unknown
- 2021-01-14 AU AU2021208553A patent/AU2021208553A1/en active Pending
- 2021-01-14 CN CN202310017475.0A patent/CN116655799A/zh active Pending
- 2021-01-14 US US17/792,976 patent/US20240043489A1/en active Pending
- 2021-01-14 CN CN202180021141.XA patent/CN115298205A/zh active Pending
- 2021-01-14 IL IL294763A patent/IL294763A/en unknown
- 2021-01-14 JP JP2022543432A patent/JP2023511074A/ja active Pending
- 2021-01-14 IL IL294617A patent/IL294617A/en unknown
- 2021-01-14 WO PCT/US2021/013478 patent/WO2021146455A1/en not_active Ceased
- 2021-01-14 EP EP21704141.7A patent/EP4090673A1/en active Pending
- 2021-01-14 MX MX2022008773A patent/MX2022008773A/es unknown
- 2021-01-14 CA CA3164522A patent/CA3164522A1/en active Pending
- 2021-01-14 KR KR1020227028145A patent/KR20220128413A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511074A5 (https=) | ||
| JP2019513014A5 (https=) | ||
| Le et al. | The dual personalities of matrix metalloproteinases in inflammation | |
| Koivunen et al. | Tumor targeting with a selective gelatinase inhibitor | |
| Chen et al. | Seprase complexes in cellular invasiveness | |
| Stefanidakis et al. | Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression | |
| Ellerbroek et al. | Membrane associated matrix metalloproteinases in metastasis | |
| Kaplan et al. | Pathways for bradykinin formation and inflammatory disease | |
| Corcoran et al. | MMP-2: expression, activation and inhibition | |
| D'ortho et al. | Membrane‐type matrix metalloproteinases 1 and 2 exhibit broad‐spectrum proteolytic capacities comparable to many matrix metalloproteinases | |
| Laurenzana et al. | Endothelial progenitor cells in sprouting angiogenesis: proteases pave the way | |
| Sidenius et al. | The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy | |
| JP2021087429A5 (https=) | ||
| JP2023526428A5 (https=) | ||
| Schmitt et al. | Urokinase‐type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis | |
| Duncan et al. | Human matrix metalloproteinase‐9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form | |
| Chen et al. | DPPIV, seprase, and related serine peptidases in multiple cellular functions | |
| IL307276B2 (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| Djuric et al. | Overview of MMP Biology and Gene Associations in | |
| Murphy et al. | Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail | |
| JP2023511074A (ja) | 切断可能リンカーを含むサイトカインプロドラッグ | |
| JP2024528660A5 (https=) | ||
| JP2004520031A5 (https=) | ||
| Del Rosso et al. | The urokinase-type plasminogen activator system and inflammatory joint diseases | |
| Smith et al. | Proteinase and peptidase inhibition: recent potential targets for drug development |